Farmas USA

Futuros medio punto abajo ... 7 h para apertura ... tic tac tic tac ...

ZIOP

He leido que no van a hacer la presentación que tenían planeada este jueves en Leerink, mi opinión es que no van porque tendrán otras cosas que hacer, pero como ya sabeis como se mueve este stock, en base a rumores infundados, ya estan pumpeando diciendo que si no van es porque hay un deal, etc, etc...

XBI

SPY

Tal y como las veo, ambas tocando ayer resistencia bajista ... ahora los futuros -0,5% ...  ya veremos si cambian en 3 h ....

RDUS

El fondo BB Biotech sigue comprando acciones 

 Insider BIOTECH GROWTH N V reports buying 75,000 shares of $RDUS at $34.38 for a total cost of $2,578,762.5

ADXS

Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

• Advaxis reaches important regulatory milestone for axalimogene filolisbac with submission of Conditional MAA to treat metastatic cervical cancer in patients who progress beyond first-line therapy
• The MAA submission is centered around the encouraging results from the GOG-0265 study
• Each year, more than 24,000 women in Europe die from metastatic cervical cancer1

https://www.businesswire.com/news/home/20180213005807/en/Advaxis-Submits-Conditional-Marketing-Authorization-Application-Axalimogene

aún duele más esos 2.42 del otro día ;)

otra vez será.

más me duele a mi llevarlas en 3,8x...jaja

De momento +9% con 9k cromos. Con recuperar la pasta ya daría palmas con las orejas (evidentemente no hablo de hoy mismo)

ADXS

ADXS

the company will continue assessing partnership opportunities for the potential commercialization of axalimogene filolisbac in Europe.

The company has also decided to align and simplify its strategy by using axalimogene filolisbac exclusively in all ongoing and planned HPV-related cancer clinical trials, including the upcoming ADVANCE trial, previously planned with ADXS-DUAL. The strategic decision to harmonize all trials to axalimogene filolisbac is based on its clinical profile to date in over 250 patients, and its demonstration of similar activity in both HPV 16 and 18 subtypes in GOG-0265. The company believes that harmonizing to a single product candidate for all HPV-related programs will streamline developmental, regulatory and commercialization strategies.

PS: no te quejes de ese precio, que me dan ganas de morderte la yugular. En dos días estás fuera